Eli Lilly publishes application on IL-10 agents with CAR T cell therapy.
The filing
Eli Lilly and Company published an application on November 12, 2026, describing compositions and methods for using IL-10 agents with chimeric antigen receptor cell therapy. The application is available at US20260356902A1 (opens in a new tab).
This filing’s full text wasn’t read for this issue, so its claims and the applicant’s background aren’t shown. Both are in the record, under Sources.